Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Keating

Showing results (361-370 of 436) with videos related to

Pageof 44
Sort By:
British Journal of Clinical Pharmacology|May 18, 2007
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment responseD R Mould, A Baumann, J Kuhlmann, et al.
Cancer|January 1, 1990
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemiaH M Kantarjian, R L Walters, M J Keating, et al.
Journal of Neuroscience Methods|February 1, 1987
Signal processing technique to extract neuronal activity from noiseS H Chung, L C Jones, B J Hammond, et al.
Cancer|June 15, 1981
A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemiaM J Keating, T L Smith, K B McCredie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogeneticsS M Kornblau, P F Thall, Z Estrov, et al.
Cancer|January 1, 1981
Natural history of central nervous system acute leukemia in adultsD J Stewart, M J Keating, K B McCredie, et al.
Leukemia Research|January 1, 1986
Prognostic factors for survival of 194 patients with low infiltrate leukemiaA M Maddox, M J Keating, T L Smith, et al.
Hematologic Pathology|January 1, 1987
Acute myelomonocytic leukemia associated with abnormalities of chromosome 16: a light and electron microscopic studyW T Dalton, M J Ahearn, A Cork, et al.
Blood|March 1, 1993
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemiaH M Kantarjian, M Beran, A Ellis, et al.
Leukemia & Lymphoma|January 1, 1994
The expanding role of fludarabine in hematologic malignanciesM J Keating, S O'Brien, L E Robertson, et al.
Pageof 44

Showing results (361-370 of 436) with videos related to

Sort By:
Pageof 44
British Journal of Clinical Pharmacology|May 18, 2007
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment responseD R Mould, A Baumann, J Kuhlmann, et al.
Cancer|January 1, 1990
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemiaH M Kantarjian, R L Walters, M J Keating, et al.
Journal of Neuroscience Methods|February 1, 1987
Signal processing technique to extract neuronal activity from noiseS H Chung, L C Jones, B J Hammond, et al.
Cancer|June 15, 1981
A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemiaM J Keating, T L Smith, K B McCredie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogeneticsS M Kornblau, P F Thall, Z Estrov, et al.
Cancer|January 1, 1981
Natural history of central nervous system acute leukemia in adultsD J Stewart, M J Keating, K B McCredie, et al.
Leukemia Research|January 1, 1986
Prognostic factors for survival of 194 patients with low infiltrate leukemiaA M Maddox, M J Keating, T L Smith, et al.
Hematologic Pathology|January 1, 1987
Acute myelomonocytic leukemia associated with abnormalities of chromosome 16: a light and electron microscopic studyW T Dalton, M J Ahearn, A Cork, et al.
Blood|March 1, 1993
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemiaH M Kantarjian, M Beran, A Ellis, et al.
Leukemia & Lymphoma|January 1, 1994
The expanding role of fludarabine in hematologic malignanciesM J Keating, S O'Brien, L E Robertson, et al.
Pageof 44